ZB-002 is under clinical development by Zenas BioPharma (USA) and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZB-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZB-002 (Xtend-TNF) (XmAb-6755) is under development for the treatment of autoimmune disorders. The drug candidate targets tumor necrosis factor-alpha receptor. Xtend-TNF is a half-life enhanced version of Humira (adalimumab). It is based on Xmab and Xtend technology. It is administered through subcutaneous route.
Zenas BioPharma (USA) overview
Zenas BioPharma (USA) (Zenas) is a biopharmaceutical company. The company focuses on a rapidly advancing portfolio of innovative therapeutics. Its product pipeline includes Obexelimab (XmAb5871), ZB002, ZB004, ZB001 (IV)3, ZB011 (SC)3, and ZB0054. The company’s Obexelimab demonstrated inhibition of B-cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases and IgG4-related disease (IgG4-RD); ZB001 is same as insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb) which is used in treatment of thyroid eye disease (TED); ZB002 used in anti-TNFa therapies; and ZB004 used in CTLA4-Ig fusion protein therapies. It operated across the US. Zenas is headquartered in Waltham, Massachusetts, the US.
For a complete picture of ZB-002’s drug-specific PTSR and LoA scores, buy the report here.